HilleVax

HilleVax is  focused on the development and commercialization of novel vaccines. The company’s lead program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

HilleVax is  focused on the development and commercialization of novel vaccines. The company’s lead program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.